Under a new agreement, licenced manufacturers will be able to supply generic versions of ViiV’s long-acting cabotegravir HIV pre-exposure prophylaxis (PrEP) medication to developing nations.
List view / Grid view
tenofovir disoproxil fumarate (TDF)
The trial was stopped because the data suggested that injections of the long-acting antiretroviral drug cabotegravir (CAB LA) are highly effective for HIV pre-exposure prophylaxis (PrEP) in women.
Tenofovir disoproxil fumarate (TDF) does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery.
Clinical trial will compare three antiretroviral drug regimens...